NUSA DUA BALI (8/20/2019) - Bio Farma A state-owned Enterprises (BUMN) pharmaceutical from Indonesia will sign a Memorandum of Understanding (MoU) with two pharmaceutical companies from the African continent that are Bahari Pharma ltd from Tanzania and Biovaccines from Nigeria. The forms of cooperation include product registration, distribution of vaccines in the form of finished products and Pre formulated bulk (intermediate products), and technology transfer for independent vaccine production in African countries.
From the release of Bio Farma, the signing of this MoU was carried out by The Acting of Bio Farma President Director, Juliman, The CEO of Bahari Pharma Ltd., Tanzania, Churchill Katzawa and The CEO of Bio Vaccines Nigeria Ltd, Nigeria, Oyewali Tomori, and witnessed by The President of Indonesia Joko Widodo and the officials from each country, in the Indonesia Africa Infrastructure Dialogue event that is held in Nusa Dua Bali 21 - 22 of August 2019.
Juliman said the collaboration by expanding Bio Farma's market share in the Africa continent was the result of collaboration with the Indonesian Ministry of Foreign Affairs and vaccine producers from Tanzania and Nigeria through B2B cooperation with a total collaboration value of 7.5 Million USD.
Bio Farma's collaboration with vaccine producers from Africa was motivated by a directive from Joko Widodo in a state address at the House of Representatives (DPR) / People’s Consultative Assembly (MPR) Building on August 16, 2019, which stated that State-Owned Enterprises and local entrepreneurs should be able to expand into the global arena to fly the red and white in Africa.
Besides, several countries in Africa still have health problems / are still trying to improve the standard of living of their people, especially in the health sector, for the prevention of infectious diseases, and Indonesia has a vaccine producer, Bio Farma, which has been qualified by WHO.
"The Africa continent has indeed become one of the largest Bio Farma consumers, there are around 54 countries in Africa, which have used Bio Farma products, through purchases from UNICEF, with products that are absorbed, among others, polio vaccines, measles and diphtheria, tetanus and Pertussis (DTP) With the MoU with pharmaceutical companies from Tanzania and Nigeria, Bio Farma's market share is expected to increase because cooperation will lead to market expansion, starting from bilateral cooperation to finish product distribution, until later the initiation of cooperation towards the independence of vaccine production, as steps to increase the value of exports and sustainable turnover, for Bio Farma ", said Juliman. (Pun)